196 related articles for article (PubMed ID: 34719787)
21. Pathology of Cholangiocarcinomas.
Guedj N
Curr Oncol; 2022 Dec; 30(1):370-380. PubMed ID: 36661679
[TBL] [Abstract][Full Text] [Related]
22. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
23. Cholangiocarcinoma: a pathologists point of view.
Hrudka J; Sticová E
Rozhl Chir; 2022; 101(10):478-487. PubMed ID: 36402559
[TBL] [Abstract][Full Text] [Related]
24. The pathways of genetic transformation in cholangiocarcinogenesis.
Serafini FM; Radvinsky D
Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
[TBL] [Abstract][Full Text] [Related]
25. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
[TBL] [Abstract][Full Text] [Related]
26. Cholangiocarcinoma Prognosis Varies over Time Depending on Tumor Site and Pathology.
Kaneko R; Sato Y; Kobayashi Y
J Gastrointestin Liver Dis; 2018 Mar; 27(1):59-66. PubMed ID: 29557416
[TBL] [Abstract][Full Text] [Related]
27. Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.
Lin Y; Peng L; Dong L; Liu D; Ma J; Lin J; Chen X; Lin P; Song G; Zhang M; Liu Y; Rao J; Wei C; Lu Y; Zhang S; Ding G; Peng Z; Lu H; Wang X; Zhou J; Fan J; Wu K; Gao Q
Cancer Discov; 2022 Oct; 12(10):2350-2371. PubMed ID: 35853232
[TBL] [Abstract][Full Text] [Related]
28. Mucosal associated invariant T cells from human breast ducts mediate a Th17-skewed response to bacterially exposed breast carcinoma cells.
Zumwalde NA; Haag JD; Gould MN; Gumperz JE
Breast Cancer Res; 2018 Sep; 20(1):111. PubMed ID: 30208917
[TBL] [Abstract][Full Text] [Related]
29. Surgery of extrahepatic bile duct cancer - current evidence and recommendations.
Nikov A; Gürlich R
Rozhl Chir; 2022; 101(9):416-420. PubMed ID: 36257799
[TBL] [Abstract][Full Text] [Related]
30. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
[TBL] [Abstract][Full Text] [Related]
31. Regulators of apoptosis in cholangiocarcinoma.
Jhala NC; Vickers SM; Argani P; McDonald JM
Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
[TBL] [Abstract][Full Text] [Related]
32. Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
Sapisochin G; Ivanics T; Heimbach J
Hepatology; 2022 Feb; 75(2):455-472. PubMed ID: 34859465
[TBL] [Abstract][Full Text] [Related]
33. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines.
Yang J; Sontag D; Gong Y; Minuk GY
Ann Hepatol; 2021; 21():100265. PubMed ID: 33045415
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor-like domain multiple 7 (EGFL7): Expression and possible effect on biliary epithelium growth in cholangiocarcinoma.
Mammola CL; Vetuschi A; Pannarale L; Sferra R; Mancinelli R
Eur J Histochem; 2018 Nov; 62(4):. PubMed ID: 30504933
[TBL] [Abstract][Full Text] [Related]
35. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.
Lin J; Dai Y; Sang C; Song G; Xiang B; Zhang M; Dong L; Xia X; Ma J; Shen X; Ji S; Zhang S; Wang M; Fang H; Zhang X; Wang X; Zhang B; Zhou J; Fan J; Zhou H; Gao D; Gao Q
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863823
[TBL] [Abstract][Full Text] [Related]
36. Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma.
Kida A; Mizukoshi E; Kitahara M; Miyashita T; Goto S; Kamigaki T; Takimoto R; Asai J; Kakinoki K; Urabe T; Tomita K; Kaneko S
Int J Cancer; 2024 Feb; 154(4):738-747. PubMed ID: 37676069
[TBL] [Abstract][Full Text] [Related]
37. Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease.
Alvaro D; Bragazzi MC; Benedetti A; Fabris L; Fava G; Invernizzi P; Marzioni M; Nuzzo G; Strazzabosco M; Stroffolini T;
Dig Liver Dis; 2011 Jan; 43(1):60-5. PubMed ID: 20580332
[TBL] [Abstract][Full Text] [Related]
38. [Gallbladder and bile duct carcinoma. Biology and pathology].
Tannapfel A; Wittekind C
Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
[TBL] [Abstract][Full Text] [Related]
39. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of Cholangiocarcinoma Immune Biology.
Vita F; Olaizola I; Amato F; Rae C; Marco S; Banales JM; Braconi C
Cells; 2023 Mar; 12(6):. PubMed ID: 36980187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
